Hikma appoints Julie Hill, as Senior Vice President, Corporate Quality Compliance/Health and Safety
London 1 February 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that Julie Hill has been appointed Senior Vice President, Corporate Quality Compliance/Health and Safety, effective immediately.
Julie will report to Hikma’s CEO, Riad Mishlawi, and she will also join the company’s senior management as a member of Hikma’s Executive Committee.
“Julie’s appointment to this role is a great recognition of her outstanding leadership qualities, valuable insights, and her ability to contribute significantly to Hikma’s continued growth and success,” said Riad Mishlawi, Hikma’s CEO.
Julie joined Hikma through the 2016 acquisition of Roxane Laboratories and most recently served as Vice President, Quality, for Hikma’s Generics business. Under Julie’s leadership, Hikma’s Generics team and Columbus facility have had the distinction of achieving many successful quality inspections from the US Food and Drug Administration and the regulatory bodies of multiple other nations.